BioSpace News Archive

REGENXBIO Inc. announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a podium presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology 2019 Annual Meeting in San Francisco, CA.

Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eyes extended to four months or longer without receiving retreatment

Monterey Health Center announced a recent event that may have impacted the privacy of personal information relating to certain current and former patients.

The global pharmaceutical contract packaging market is expected to post a CAGR of more than 17% during the period 2019-2023, according to the latest market research report by Technavio. Request a free sample report.

On Wednesday, Oct. 9, Rep. Lucy McBath (GA-06) hosted a conversation with AARP Georgia members and volunteers in Georgia’s Sixth Congressional District to talk about the rising cost of prescription drugs

FibroGen, Inc., announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2019 taking place from November 5-10 in Washington D.C.

Sema4, a patient-centered health intelligence company, today announced the launch of Expanded Carrier Screen with Personalized Residual Risk, one of the most comprehensive and highly accurate carrier screening options available, to provide physicians and their patients with enhanced risk assessment analysis designed to inform family planning decisions.

Specialdocs Consultants, a pioneer in concierge medicine transitions and ongoing management, announces two key appointments to its executive team: Dave Farr as vice president of business development and Shirin Zarinkia as vice president of strategy.

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics

Spherix Incorporated (Nasdaq: SPEX) today announced that on October 2, 2019, the Board of Directors of Spherix Incorporated (“Spherix”) approved a distribution to Spherix stockholders of 100,000 shares of Hoth Therapeutics, Inc. (“Hoth”) held by Spherix.